04

2024

-

08

Qin Jiangjiang of the Chinese Academy of Sciences provides the largest single-cell dataset of metastatic GACs to date, linking iron death to disease progression and immunotherapy response!

Author:


Gastric adenocarcinoma (GAC) metastasis results in high morbidity and mortality. The development of innovative and effective therapies requires a comprehensive understanding of the tumor and immunobiology of advanced GAC.However, collecting matched specimens from patients with late-stage treatment naïve GAC is a major challenge, limiting the scope of current studies focused primarily on localized tumors. This gap prevents a deeper understanding of the dynamics of GAC transfer.

On August 1, 2024, Wang linghua, Jaffer A. Ajani, Pawel K. Mazur, and Qin jiangjiang, institute of basic medicine and oncology, Chinese academy of sciences, jointly communicatedGastroenterology(IF=17.6)Published online entitled“Atlas of metastatic gastric cancer links ferroptosis to disease progression and immunotherapy response”The research paper,The study utilizesThe mapping of metastatic gastric cancer links iron death to disease progression and immunotherapy response.

Hepatocellular carcinoma and peritoneal metastasis exhibit different properties and the dynamics of TME phenotypes in cancer cells, supporting the idea that cancer cells and their local TMEs co-evolve at metastatic sites. The study also revealed different activation of cancer meta-programs in metastasis. The researchers observed that cancer cells evade iron death by upregulating GPX4 during GAC progression. Conditional removal of Gpx4 or pharmacological inhibition of iron death resistance can significantly reduce tumor growth and metastasis progression. In addition, iron death enhances the efficacy of CAR-T cell therapy.The study provides the largest single-cell dataset of metastatic GACs to date. High-resolution molecular and cellular dynamics mapping of GAC transfer reveals the rationale for targeting iron death defense in combination with CAR-T cell therapy as a novel therapeutic strategy with potentially great clinical implications.

Gastric adenocarcinoma (GAC) is usually diagnosed at an advanced stage and often shows resistance to treatment. The liver (LM) and peritoneum (PC) are the most common sites of metastasis, accounting for about 80% of all metastases. Late GAC with LM and/or PC is associated with poor prognosis, resulting in a 5-year survival rate of less than 5%. Current treatment options for advanced GAC after first-line therapy are of limited effectiveness, and recently combined with immunotherapy have benefited only a small fraction of patients. Thus, a detailed understanding of the tumor and immunobiology of late-stage GAC may facilitate the development of new, more effective therapies.

Previous single-cell studies have focused mainly on localized tumors with little or no metastases of GAC origin, so our understanding of metastatic GAC is relatively limited. In a recent study, researchers performed single-cell analysis of PC ascites cells from 20 GAC patients, revealing heterogeneous cancer cell lineage states and linking the composition of cancer cell state 120 to intratumoral heterogeneity (ITH) and survival outcomes.However, the study did not include any paired primary tumors, only focused on PC, and most patients had received multiple treatments. There is a need for a comprehensive identification of primary GACs paired with PC and/or LM, especially in treatment-naïve patients.

The study constructs a single-cell multi-omics atlas of late-stage GAC, depicts the evolution of malignant progression, and uncovers the rationale for combination therapy that targets iron death resistance versus next-generation CAR-T cell therapy. Although advanced GAC has a poor response to ICB therapy compared with melanoma and lung cancer, the possibility that targeting iron death can improve the efficacy of ICB therapy is not excluded. The study highlights the potential for high-resolution mapping of the molecular and cellular mechanisms of GAC pathogenesis to identify new therapeutic opportunities.

Chongqing Chongfan Technology Co., Ltd. Optical platform film thickness meter OCT optical coherence tomography LabVIEW control